Research Antibodies and Reagents Global Market Report 2024

The research antibodies and reagents market size has grown strongly in recent years. It will grow from $15.19 billion in 2023 to $16.44 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period can be attributed to the rise in pharmaceutical research and development (R&D) expenditure, an increase in the geriatric population, heightened healthcare expenditure, augmented government funds allocated for research, and a growth in the number of healthcare facilities.

The research antibodies and reagents market size is expected to see strong growth in the next few years. It will grow to $24.04 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The anticipated growth in the forecast period can be ascribed to factors such as the growing geriatric population, heightened prevalence of cancer and chronic diseases, increased spending on research and development, a surge in healthcare expenditure, augmented financing for proteomics ventures, a rising demand for personalized medicine, and the emergence of infectious diseases. Key trends expected in the forecast period include a focus on incorporating nanotechnology for the identification of low-abundant molecules, the introduction of innovative technological products to enhance sales and profitability, emphasis on utilizing advanced antibody purification technologies, consideration of acquisitions and mergers with other research agencies and centers, and investments in research and development labs and initiatives.

The expected expansion in the research antibodies and reagents market can be attributed to the increasing investment in medical and health research and development (R&D). In the realm of life science research, antibodies and reagents play indispensable roles in the exploration of biological processes or the investigation of causes of diseases through meticulous experimentation, observation, laboratory work, analysis, and testing. As an illustration, a report published by the Congressional Budget Office in April 2021 indicated that pharmaceutical companies globally were projected to invest $83 billion in research and development activities. Consequently, the heightened investment in healthcare research and development is poised to amplify the utilization of the research antibodies and reagents market.

The growth of the research antibodies and reagents market is further driven by the increasing demand for personalized medicine. Personalized medicine tailors medical treatment to an individual's unique genetic makeup, providing more effective and precise healthcare interventions. Research antibodies and reagents play a pivotal role in shaping precision medicine approaches, facilitating targeted diagnostics and therapies based on individual patient profiles. As evidenced in 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% of the therapeutic NMEs (12 out of 35) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the surge in demand for personalized medicine propels the growth of the research antibodies and reagents market.

The research antibodies and reagents market present growth opportunities during the forecast period, driven by technological advancements in the purification of antibodies and reagents. A significant challenge faced by the industry is the issue of irreproducible antibodies and reagents, which can impact research outcomes. In April 2021, the UK-based Native Antigen Company addressed this challenge by launching the SARS-CoV-2 Neutralization Assay Development Kit. This kit includes essential reagents for measuring Spike-antibody binding, focusing on the RBD-ACE2 interaction to identify and qualitatively measure neutralizing antibodies.

Major players in the research antibodies and reagents market are concentrating on developing reagent solutions for immunohistochemistry to gain a competitive advantage. These reagent solutions typically comprise antibodies and blocking agents in a buffered solution. For example, in March 2023, the UK-based Aptamer Group PLC introduced Optimer-Fc, designed for use in automated immunohistochemistry workflows. Optimer-Fc is an innovative solution combining an Optimer binder with the Fc domain of an antibody, serving as a viable substitute for primary detecting antibodies in various IHC applications. This approach allows seamless integration into existing workflows, replacing the primary detecting antibody without compromising the process's integrity.

In February 2022, the US-based Rockland Immunochemicals, Inc., acquired Germany-based Antibodies-Online GmbH, marking a strategic move to enhance capabilities in designing, developing, and manufacturing antibodies and assays. This acquisition leverages Antibodies-Online's e-commerce brand, supplier network, and technology stack, providing customers with improved capabilities supported by comprehensive data sets, enhancing the overall customer experience and strengthening their market strategy.

Major companies operating in the research antibodies and reagents market report are Thermo Fisher Scientific Inc., Abcam PLC, Cell Signaling Technology, Inc., Merck KGaA, Santa Cruz Biotechnology, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Johnson & Johnson, F. Hoffmann-La Roche AG, Becton Dickinson and Company, Biocon, Immunochina, Takara Bio, GE Healthcare, Zhejiang Kangte Biotechnology Co., Ltd., Wuxi Tech-star Technology Co., Ltd., Shaanxi Bloom Tech Co., Ltd., PerkinElmer Inc., Lonza Group AG, GenScript Biotech Corporation, Bio-Techne Corporation.

North America was the largest region in the research antibodies and reagents market in 2023. The regions covered in the research antibodies and reagents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the research antibodies and reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The primary technologies employed in research antibodies and reagents include western blot, immunofluorescence, immunohistochemistry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), multiplex immunosorbent assay, immunoprecipitation, and others. Western blot, also known as western blotting, is an analytical technique in molecular biology and immunogenetics used to detect specific proteins in a sample of tissue homogenate or extract. These technologies find applications in various fields such as proteomics, drug discovery and development, and genomics. Additionally, they are widely utilized across sectors including the pharmaceutical and biotechnology industry, academic and research institutes, and contract research organizations (CROs).

The research antibodies and reagents market research report is one of a series of new reports that provides research antibodies and reagents market statistics, including research antibodies and reagents industry global market size, regional shares, competitors with a research antibodies and reagents market share, detailed research antibodies and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the research antibodies and reagents industry. This research antibodies and reagents market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The research antibodies and reagents market consists of sales of buffers, fixatives, solvents, and enzymes. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.